top of page

ACTIVITIES

Lyophilization development feasibility study for heat-stable tablet formulation 

An essential characteristic to ensure the affordability of the vaccine in low- and middle-income countries is to make it suitable for distribution without the need of cold chain. 

Therefore, the suitable pH and salt concentrations as well as stabilizing excipients will be determined to generate a liquid formulation suitable for freeze-drying. In addition, the appropriate dose and concentration of buffer for a neutralization of stomach acid will be determined. The liquid formulation will be filled in preformed blisters sheets and freeze dried to generate lyophilized fast-dissolving tablets. 

Partners involved

Eveliqure%20Logo%20Square_edited.jpg
PATH Logo Rectangle.png

Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

Thanks for subscribing! If you have any questions or would like to unsubscribe contact us at communication@euvaccine.eu.

  • LinkedIn - White Circle
  • Twitter - White Circle
EU emblem_flag_yellow_high (1).jpg

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568

© 2024 European Vaccine Initiative. Designed by European Vaccine Initiative

bottom of page